Head to Head Review: Oriental Rise (NASDAQ:ORIS) and Medifast (NYSE:MED)

Oriental Rise (NASDAQ:ORISGet Free Report) and Medifast (NYSE:MEDGet Free Report) are both small-cap consumer staples companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk and earnings.

Valuation and Earnings

This table compares Oriental Rise and Medifast”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Oriental Rise $12.22 million 0.04 $680,000.00 N/A N/A
Medifast $346.10 million 0.31 -$18.67 million ($1.83) -5.31

Oriental Rise has higher earnings, but lower revenue than Medifast.

Profitability

This table compares Oriental Rise and Medifast’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Oriental Rise N/A N/A N/A
Medifast -5.78% -4.80% -3.83%

Institutional and Insider Ownership

95.5% of Medifast shares are owned by institutional investors. 3.7% of Medifast shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk and Volatility

Oriental Rise has a beta of 1.54, indicating that its stock price is 54% more volatile than the S&P 500. Comparatively, Medifast has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for Oriental Rise and Medifast, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oriental Rise 1 0 0 0 1.00
Medifast 1 1 0 1 2.33

Medifast has a consensus target price of $12.00, suggesting a potential upside of 23.39%. Given Medifast’s stronger consensus rating and higher possible upside, analysts plainly believe Medifast is more favorable than Oriental Rise.

Summary

Medifast beats Oriental Rise on 7 of the 12 factors compared between the two stocks.

About Oriental Rise

(Get Free Report)

Oriental Rise Holdings Ltd. engages in the cultivation, processing, and sale of tea leaves and tea products. It operates through the Primarily-Processes Teas and Refined Teas segments. The company was founded by Chun Sun Wong, Wai Kwong Fong and Deming Zhou on January 25, 2019 and is headquartered in Ningde, China.

About Medifast

(Get Free Report)

Medifast, Inc., through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names. The company markets its products through point-of-sale transactions, as well as through ecommerce platform. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.

Receive News & Ratings for Oriental Rise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oriental Rise and related companies with MarketBeat.com's FREE daily email newsletter.